NO995635L - 3(5)-heteroaryl-substituerte pyrazoler som p38- kinaseinhibitorer - Google Patents
3(5)-heteroaryl-substituerte pyrazoler som p38- kinaseinhibitorerInfo
- Publication number
- NO995635L NO995635L NO995635A NO995635A NO995635L NO 995635 L NO995635 L NO 995635L NO 995635 A NO995635 A NO 995635A NO 995635 A NO995635 A NO 995635A NO 995635 L NO995635 L NO 995635L
- Authority
- NO
- Norway
- Prior art keywords
- heteroaryl
- kinase inhibitors
- substituted pyrazoles
- pyrazoles
- substituted
- Prior art date
Links
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 150000003217 pyrazoles Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4753597P | 1997-05-22 | 1997-05-22 | |
PCT/US1998/010807 WO1998052937A2 (fr) | 1997-05-22 | 1998-05-22 | PYRAZOLES 3(5)-HETEROARYL SUBSTITUEES UTILISEES COMME INHIBITEURS DE KINASE p38 |
Publications (2)
Publication Number | Publication Date |
---|---|
NO995635L true NO995635L (no) | 1999-11-17 |
NO995635D0 NO995635D0 (no) | 1999-11-17 |
Family
ID=21949533
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO995635A NO995635D0 (no) | 1997-05-22 | 1999-11-17 | 3(5)-heteroaryl-substituerte pyrazoler som p38-kinaseinhibitorer |
Country Status (14)
Country | Link |
---|---|
US (1) | US5932576A (fr) |
EP (1) | EP0983260A2 (fr) |
JP (1) | JP2002502379A (fr) |
KR (1) | KR20010012808A (fr) |
CN (1) | CN1264376A (fr) |
AR (1) | AR037061A1 (fr) |
AU (1) | AU755498B2 (fr) |
BR (1) | BR9809451A (fr) |
CA (1) | CA2288741A1 (fr) |
IL (1) | IL132736A0 (fr) |
NO (1) | NO995635D0 (fr) |
PL (1) | PL336990A1 (fr) |
RU (1) | RU2249591C2 (fr) |
WO (1) | WO1998052937A2 (fr) |
Families Citing this family (118)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5559137A (en) * | 1994-05-16 | 1996-09-24 | Smithkline Beecham Corp. | Compounds |
US6514977B1 (en) * | 1997-05-22 | 2003-02-04 | G.D. Searle & Company | Substituted pyrazoles as p38 kinase inhibitors |
AU7726898A (en) | 1997-05-22 | 1998-12-11 | G.D. Searle & Co. | Pyrazole derivatives as p38 kinase inhibitors |
US6979686B1 (en) | 2001-12-07 | 2005-12-27 | Pharmacia Corporation | Substituted pyrazoles as p38 kinase inhibitors |
US6087496A (en) * | 1998-05-22 | 2000-07-11 | G. D. Searle & Co. | Substituted pyrazoles suitable as p38 kinase inhibitors |
AU7966198A (en) | 1997-06-13 | 1998-12-30 | Smithkline Beecham Corporation | Novel pyrazole and pyrazoline substituted compounds |
US6339099B1 (en) * | 1997-06-20 | 2002-01-15 | Dupont Pharmaceuticals Company | Guanidine mimics as factor Xa inhibitors |
US7301021B2 (en) | 1997-07-02 | 2007-11-27 | Smithkline Beecham Corporation | Substituted imidazole compounds |
ES2154253T3 (es) * | 1997-12-22 | 2012-01-27 | Bayer Healthcare Llc | Inhibición de la actividad de p38 cinasa usando ureas heterocíclicas sustituidas. |
MY132496A (en) * | 1998-05-11 | 2007-10-31 | Vertex Pharma | Inhibitors of p38 |
US7605149B1 (en) | 1998-07-13 | 2009-10-20 | University Of South Florida | Modulation of the phospholipase A2 pathway as a therapeutic |
EP1119254A4 (fr) | 1998-10-07 | 2004-05-12 | Smithkline Beecham Corp | Nouveau traitement pour la gestion des accidents vasculaires cerebraux |
SA99191255B1 (ar) * | 1998-11-30 | 2006-11-25 | جي دي سيرل اند كو | مركبات سيليكوكسيب celecoxib |
CA2355075C (fr) | 1998-12-16 | 2009-12-08 | Aventis Pharma Limited | Acetals heteroaryl-cycliques |
CN1326848C (zh) * | 1998-12-25 | 2007-07-18 | 帝国脏器制药株式会社 | 氨基吡唑衍生物 |
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
CA2359244C (fr) | 1999-01-13 | 2013-10-08 | Bayer Corporation | Diphenyle urees a substitution .omega.-carboxy aryle en tant qu'inhibiteurs de la kinase p38 |
JP2000281588A (ja) * | 1999-03-30 | 2000-10-10 | Sankyo Co Ltd | ガンの予防又は治療薬及びそのスクリーニング方法 |
US7122666B2 (en) | 1999-07-21 | 2006-10-17 | Sankyo Company, Limited | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses |
US6808902B1 (en) | 1999-11-12 | 2004-10-26 | Amgen Inc. | Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules |
WO2001038312A1 (fr) | 1999-11-23 | 2001-05-31 | Smithkline Beecham Corporation | COMPOSES DE 3,4-DIHYDRO-(1H)QUINAZOLINE-2-ONE UTILISES COMME INHIBITEURS DE LA KINASE CSBP/p38 |
AU2001236720A1 (en) * | 2000-02-05 | 2001-08-14 | Bemis, Guy | Compositions useful as inhibitors of erk |
NZ514583A (en) * | 2000-02-05 | 2004-05-28 | Vertex Pharma | Pyrazole compositions useful as inhibitors of ERK |
PE20020506A1 (es) * | 2000-08-22 | 2002-07-09 | Glaxo Group Ltd | Derivados de pirazol fusionados como inhibidores de la proteina cinasa |
US6670357B2 (en) | 2000-11-17 | 2003-12-30 | Bristol-Myers Squibb Company | Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors |
US6867300B2 (en) * | 2000-11-17 | 2005-03-15 | Bristol-Myers Squibb Company | Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors |
US20040087623A1 (en) * | 2001-02-02 | 2004-05-06 | Gellibert Francoise Jeanne | Pyrazole derivatives against tgf overexpression |
EP1389206B1 (fr) * | 2001-04-13 | 2006-09-13 | Vertex Pharmaceuticals Incorporated | Inhibiteurs de c-jun n-terminal kinases (jnk) et d'autres proteines kinases |
EP1382603B1 (fr) * | 2001-04-26 | 2008-07-23 | Eisai R&D Management Co., Ltd. | Compose azote a anneaux condenses possedant un groupe pyrazolyle et servant de substituant, et composition medicale le comprenant |
GB0112348D0 (en) * | 2001-05-19 | 2001-07-11 | Smithkline Beecham Plc | Compounds |
YU103003A (sh) | 2001-06-26 | 2006-05-25 | Abgenix Inc. | Antitela za opgl |
WO2003011854A1 (fr) * | 2001-08-03 | 2003-02-13 | Vertex Pharmaceuticals Incorporated | Inhibiteurs de kinase derives du pyrazole et leurs utilisations |
EP1419770A4 (fr) * | 2001-08-24 | 2005-08-03 | Shionogi & Co | Agent d'acc l ration de l'expression de apo ai |
US6897318B2 (en) | 2001-09-25 | 2005-05-24 | Pharmacia Corporation | Process for making substituted pyrazoles |
US7057049B2 (en) | 2001-09-25 | 2006-06-06 | Pharmacia Corporation | Process for making substituted pyrazoles |
GB0124939D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124934D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124933D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124936D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124931D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124941D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124938D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124932D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
EP1439863B1 (fr) * | 2001-10-29 | 2011-01-12 | Boehringer Ingelheim International GmbH | Proteines homologues de mnk kinase impliquees dans la regulation de l'homeostase energetique et du metabolisme des organites |
JP4399265B2 (ja) * | 2001-12-21 | 2010-01-13 | ヴァーナリス(ケンブリッジ)リミテッド | 3,4−ジアリールピラゾール、および癌の治療におけるそれらの使用 |
DK1478358T3 (da) | 2002-02-11 | 2013-10-07 | Bayer Healthcare Llc | Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese |
ATE485275T1 (de) | 2002-02-12 | 2010-11-15 | Glaxosmithkline Llc | Nicotinamide und deren verwendung als p38 inhibitoren |
AR039241A1 (es) * | 2002-04-04 | 2005-02-16 | Biogen Inc | Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos |
US20050124620A1 (en) * | 2002-04-09 | 2005-06-09 | Martyn Frederickson | Pharmaceutical compounds |
DK1497019T3 (en) | 2002-04-23 | 2015-08-03 | Bristol Myers Squibb Co | PYRROLO-TRIAZINANILINE COMPOSITIONS USED AS KINase INHIBITORS |
WO2003095455A2 (fr) * | 2002-05-10 | 2003-11-20 | Smithkline Beecham Corporation | Composes therapeutiques |
DE60310730T2 (de) | 2002-07-09 | 2007-05-16 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmazeutische zusammensetzungen aus anticholinergica und p38 kinase hemmern zur behandlung von erkrankungen der atemwege |
GB0217757D0 (en) | 2002-07-31 | 2002-09-11 | Glaxo Group Ltd | Novel compounds |
UA80295C2 (en) * | 2002-09-06 | 2007-09-10 | Biogen Inc | Pyrazolopyridines and using the same |
PL379544A1 (pl) * | 2002-09-09 | 2006-10-02 | Amgen Inc. | 1,4,5-podstawione pochodne 1,2-dihydro-pirazol-3-onu i 3-alkoksy 1H-pirazolu jako środki obniżające poziom TNF-alfa oraz interleukin do leczenia stanów zapalnych |
EA200500378A1 (ru) | 2002-09-18 | 2005-08-25 | Пфайзер Продактс Инк. | Новые соединения имидазола в качестве ингибиторов трансформирующего фактора роста (tgf) |
WO2004026306A2 (fr) | 2002-09-18 | 2004-04-01 | Pfizer Products Inc. | Nouveaux composes de pyrazole utilises comme inhibiteurs du facteur de croissance transformant (tgf) |
PL375973A1 (en) | 2002-09-18 | 2005-12-12 | Pfizer Products Inc. | Novel isothiazole and isoxazole compounds as transforming growth factor (tgf) inhibitors |
BR0314383A (pt) | 2002-09-18 | 2005-07-19 | Pfizer Prod Inc | Compostos de oxazol e tiazol como inibidores do fator de crescimento transformante(tgf) |
JP2006502236A (ja) | 2002-09-18 | 2006-01-19 | ファイザー・プロダクツ・インク | 形質転換成長因子(tgf)阻害剤としてのトリアゾール誘導体 |
CN100519552C (zh) | 2002-09-25 | 2009-07-29 | 宇部兴产株式会社 | 吡唑化合物 |
PL377848A1 (pl) | 2003-02-07 | 2006-02-20 | Daiichi Pharmaceutical Co., Ltd. | Pochodne pirazoli |
CL2004000234A1 (es) * | 2003-02-12 | 2005-04-15 | Biogen Idec Inc | Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid |
CL2004000366A1 (es) * | 2003-02-26 | 2005-01-07 | Pharmacia Corp Sa Organizada B | USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA. |
PA8595001A1 (es) | 2003-03-04 | 2004-09-28 | Pfizer Prod Inc | Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf) |
EP1606019A1 (fr) * | 2003-03-07 | 2005-12-21 | The University Court of The University of Aberdeen | Agonistes inverses de recepteurs de cannabinoides et antagonistes neutres agissant en tant qu'agents therapeutiques destines au traitement de troubles osseux |
GB0308185D0 (en) * | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
GB0308201D0 (en) * | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
GB0308186D0 (en) * | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
CA2519189C (fr) | 2003-05-07 | 2012-07-17 | Osteologix A/S | Sels de strontium solubles dans l'eau pour le traitement de maladies des cartilages et/ou des os |
PT1626714E (pt) | 2003-05-20 | 2007-08-24 | Bayer Pharmaceuticals Corp | Diarilureias para doenças mediadas por pdgfr |
US7652044B2 (en) * | 2003-06-03 | 2010-01-26 | Novartis A.G. | P-38 inhibitors |
ATE517872T1 (de) | 2003-06-26 | 2011-08-15 | Novartis Ag | Fünfgliedrige p38-kinaseinhibitoren auf heterocyclusbasis |
ES2297490T3 (es) | 2003-07-23 | 2008-05-01 | Bayer Pharmaceuticals Corporation | Omega-carboxiarildifenilurea fluoro sustituida para el tratamiento y prevencion de enfermadades y afecciones. |
ATE412642T1 (de) * | 2003-07-25 | 2008-11-15 | Novartis Ag | Inhibitoren von p-38-kinase |
GB0318814D0 (en) * | 2003-08-11 | 2003-09-10 | Smithkline Beecham Corp | Novel compounds |
US7419978B2 (en) * | 2003-10-22 | 2008-09-02 | Bristol-Myers Squibb Company | Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors |
GB0402143D0 (en) * | 2004-01-30 | 2004-03-03 | Smithkline Beecham Corp | Novel compounds |
US7504521B2 (en) * | 2004-08-05 | 2009-03-17 | Bristol-Myers Squibb Co. | Methods for the preparation of pyrrolotriazine compounds |
US20060035893A1 (en) | 2004-08-07 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders |
TW200618803A (en) | 2004-08-12 | 2006-06-16 | Bristol Myers Squibb Co | Process for preparing pyrrolotriazine aniline compounds useful as kinase inhibitors |
GEP20104973B (en) | 2004-08-12 | 2010-04-26 | Pfizer | Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors |
US20080051416A1 (en) * | 2004-10-05 | 2008-02-28 | Smithkline Beecham Corporation | Novel Compounds |
PE20060777A1 (es) | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas |
US20060178388A1 (en) * | 2005-02-04 | 2006-08-10 | Wrobleski Stephen T | Phenyl-substituted pyrimidine compounds useful as kinase inhibitors |
TW200639163A (en) | 2005-02-04 | 2006-11-16 | Genentech Inc | RAF inhibitor compounds and methods |
US20060235020A1 (en) * | 2005-04-18 | 2006-10-19 | Soojin Kim | Process for preparing salts of 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide and novel stable forms produced therein |
WO2006116355A1 (fr) * | 2005-04-22 | 2006-11-02 | Kalypsys, Inc. | Inhibiteurs ortho-terphenyle de kinase p38 et procedes de traitement des troubles inflammatoires |
GB0512429D0 (en) * | 2005-06-17 | 2005-07-27 | Smithkline Beecham Corp | Novel compound |
US7473784B2 (en) | 2005-08-01 | 2009-01-06 | Bristol-Myers Squibb Company | Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors |
WO2007027878A2 (fr) * | 2005-08-31 | 2007-03-08 | Emergent Product Development Gaithersburg Inc. | Derives de 2-aryloxyphenol 4-substitues utilises comme agents antibacteriens |
EP2388259A1 (fr) * | 2005-10-28 | 2011-11-23 | AstraZeneca AB | Derives 4-(3-aminopyrazole)pyrimidine et leur utilisation en tant qu'inhibiteurs de tyrosine kinases dans le cadre d'un traitement anticancereux |
AU2006327314A1 (en) * | 2005-12-23 | 2007-06-28 | Astrazeneca Ab | Pyrazoles for the treatment of GERD and IBS |
BRPI0708644A2 (pt) * | 2006-03-07 | 2011-06-07 | Bristol-Myers Squibb Company | compostos de pró-fármaco de anilina de pirrolotriazina úteis como inibidores de cinase |
JP2007205153A (ja) * | 2006-08-07 | 2007-08-16 | Seiki Hanbai Co Ltd | 網戸用ネットの押さえ部材 |
US8128460B2 (en) * | 2006-09-14 | 2012-03-06 | The Material Works, Ltd. | Method of producing rust inhibitive sheet metal through scale removal with a slurry blasting descaling cell |
CN101616667A (zh) * | 2006-10-27 | 2009-12-30 | 百时美施贵宝公司 | 可用作激酶抑制剂的杂环酰胺化合物 |
US7943617B2 (en) * | 2006-11-27 | 2011-05-17 | Bristol-Myers Squibb Company | Heterobicyclic compounds useful as kinase inhibitors |
MX2009008665A (es) * | 2007-02-13 | 2009-08-21 | Ab Science | Procedimiento para la sintesis de compuestos de 2-aminotiazol como inhibidores de quinasa. |
GB0702862D0 (en) * | 2007-02-14 | 2007-03-28 | Univ Aberdeen | Therapeutic compounds |
AR066016A1 (es) * | 2007-04-11 | 2009-07-15 | Alcon Res Ltd | Uso de un inhibidor del tnf alfa junto con una antihistamina para tratar la rinitis alergica y la conjuntivitis alergica |
US20090182035A1 (en) * | 2007-04-11 | 2009-07-16 | Alcon Research, Ltd. | Use of a combination of olopatadine and cilomilast to treat non-infectious rhinitis and allergic conjunctivitis |
EP1992344A1 (fr) | 2007-05-18 | 2008-11-19 | Institut Curie | P38 alpha comme cible therapeutique pour les maladies associées á une mutation de FGFR3 |
KR20150088907A (ko) | 2007-08-29 | 2015-08-03 | 센주 세이야꾸 가부시키가이샤 | 각막 내피 세포 접착 촉진제 |
MX2010011095A (es) * | 2008-04-08 | 2010-11-05 | Gruenenthal Gmbh | Derivados de sulfonamidas sustituidos. |
US8338604B2 (en) | 2008-06-20 | 2012-12-25 | Bristol-Myers Squibb Company | Imidazopyridine and imidazopyrazine compounds useful as kinase inhibitors |
JP2011525184A (ja) * | 2008-06-20 | 2011-09-15 | ブリストル−マイヤーズ スクイブ カンパニー | キナーゼ阻害剤として有用なトリアゾロピリジン化合物 |
JP2012506388A (ja) * | 2008-10-23 | 2012-03-15 | ロンザ リミテッド | 置換されたピラゾールの合成方法 |
CA2773483A1 (fr) * | 2009-10-01 | 2011-04-07 | Alcon Research, Ltd. | Compositions d'olopatadine et leurs utilisations |
EP2308866A1 (fr) | 2009-10-09 | 2011-04-13 | Bayer CropScience AG | Phenylpyri(mi)dinylpyrazoles et leur utilisation comme fongicides |
CN102762551A (zh) | 2009-12-21 | 2012-10-31 | 拜尔农作物科学股份公司 | 噻吩基吡(嘧)啶基吡唑及其用于防治植物致病菌的用途 |
AR081810A1 (es) | 2010-04-07 | 2012-10-24 | Bayer Cropscience Ag | Piridinilpirazoles biciclicos |
WO2012031057A1 (fr) | 2010-09-01 | 2012-03-08 | Bristol-Myers Squibb Company | Bms-582949 pour le traitement d'une maladie rhumatismale résistante |
AR086992A1 (es) | 2011-06-20 | 2014-02-05 | Bayer Ip Gmbh | Tienilpiri(mi)dinilpirazoles |
MX355016B (es) | 2011-10-06 | 2018-04-02 | Bayer Ip Gmbh | Heterociclilpiri(mi)dinilpirazoles como fungicidas. |
EP2763993B1 (fr) | 2011-10-06 | 2017-04-19 | Bayer Intellectual Property GmbH | Hétérocyclylpyri(mi)dinylpyrazole |
CN103360315B (zh) * | 2013-07-22 | 2015-03-04 | 山东大学 | 一种芳杂氧乙酰肼类衍生物及其制备方法与应用 |
WO2020113094A1 (fr) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Composés pyrrole et pyrazole et leurs procédés d'utilisation |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1261124B (de) * | 1961-09-22 | 1968-02-15 | Hoechst Ag | Verfahren zur Herstellung von Pyrazolen |
GB1245283A (en) * | 1968-10-04 | 1971-09-08 | Labaz | Pyrazole derivatives |
US3984431A (en) * | 1972-03-15 | 1976-10-05 | Claude Gueremy | Derivatives of pyrazole-5-acetic acid |
FR2509729A1 (fr) * | 1981-07-15 | 1983-01-21 | Pharmindustrie | Nouveau procede de preparation de derives du diphenyl-3,4 methyl-5 pyrazole |
US5051518A (en) * | 1987-05-29 | 1991-09-24 | Ortho Pharmaceutical Corporation | Pharmacologically active 2- and 3-substituted (1',5'-diaryl-3-pyrazolyl)-N-hydroxypropanamides |
PH27357A (en) * | 1989-09-22 | 1993-06-21 | Fujisawa Pharmaceutical Co | Pyrazole derivatives and pharmaceutical compositions comprising the same |
JP2753659B2 (ja) * | 1990-09-03 | 1998-05-20 | 株式会社大塚製薬工場 | ピラゾール誘導体 |
JPH04145081A (ja) * | 1990-10-06 | 1992-05-19 | Kumiai Chem Ind Co Ltd | ピラゾールカルボン酸誘導体及び除草剤 |
AU1988692A (en) * | 1991-04-24 | 1992-12-21 | E.I. Du Pont De Nemours And Company | Fungicidal pyrazoles, pyrazolines and tetrahydropyridazines |
US5356897A (en) * | 1991-09-09 | 1994-10-18 | Fujisawa Pharmaceutical Co., Ltd. | 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines |
GB9204958D0 (en) * | 1992-03-06 | 1992-04-22 | Fujisawa Pharmaceutical Co | Thiazole derivatives |
US5593992A (en) * | 1993-07-16 | 1997-01-14 | Smithkline Beecham Corporation | Compounds |
DE4328228A1 (de) * | 1993-08-23 | 1995-03-02 | Basf Ag | Verfahren zur Herstellung von Pyrazol und dessen Derivaten |
US5559137A (en) * | 1994-05-16 | 1996-09-24 | Smithkline Beecham Corp. | Compounds |
US5486534A (en) * | 1994-07-21 | 1996-01-23 | G. D. Searle & Co. | 3,4-substituted pyrazoles for the treatment of inflammation |
JPH0899975A (ja) * | 1994-08-05 | 1996-04-16 | Nippon Bayeragrochem Kk | 5員複素環置換テトラゾリノン誘導体および除草剤 |
JP3734180B2 (ja) * | 1994-12-28 | 2006-01-11 | エーザイ株式会社 | 新規ピラゾール誘導体 |
JPH11508267A (ja) * | 1995-06-26 | 1999-07-21 | 藤沢薬品工業株式会社 | ピラゾール化合物および医薬組成物 |
GB2361824B (en) * | 2000-04-27 | 2004-05-26 | Roke Manor Research | Improvements in or relating to electronic timing systems |
-
1998
- 1998-05-22 EP EP98924924A patent/EP0983260A2/fr not_active Withdrawn
- 1998-05-22 RU RU99126510/04A patent/RU2249591C2/ru not_active IP Right Cessation
- 1998-05-22 AU AU76981/98A patent/AU755498B2/en not_active Ceased
- 1998-05-22 BR BR9809451-3A patent/BR9809451A/pt not_active Application Discontinuation
- 1998-05-22 WO PCT/US1998/010807 patent/WO1998052937A2/fr not_active Application Discontinuation
- 1998-05-22 CN CN98807326A patent/CN1264376A/zh active Pending
- 1998-05-22 KR KR1019997010771A patent/KR20010012808A/ko not_active Application Discontinuation
- 1998-05-22 AR ARP980102380A patent/AR037061A1/es unknown
- 1998-05-22 PL PL98336990A patent/PL336990A1/xx unknown
- 1998-05-22 CA CA002288741A patent/CA2288741A1/fr not_active Abandoned
- 1998-05-22 IL IL13273698A patent/IL132736A0/xx unknown
- 1998-05-22 JP JP55075598A patent/JP2002502379A/ja not_active Abandoned
- 1998-05-22 US US09/083,923 patent/US5932576A/en not_active Expired - Fee Related
-
1999
- 1999-11-17 NO NO995635A patent/NO995635D0/no unknown
Also Published As
Publication number | Publication date |
---|---|
AR037061A1 (es) | 2004-10-20 |
WO1998052937A3 (fr) | 1999-03-11 |
EP0983260A2 (fr) | 2000-03-08 |
RU2249591C2 (ru) | 2005-04-10 |
US5932576A (en) | 1999-08-03 |
AU755498B2 (en) | 2002-12-12 |
PL336990A1 (en) | 2000-07-31 |
CN1264376A (zh) | 2000-08-23 |
NO995635D0 (no) | 1999-11-17 |
BR9809451A (pt) | 2000-06-20 |
IL132736A0 (en) | 2001-03-19 |
KR20010012808A (ko) | 2001-02-26 |
CA2288741A1 (fr) | 1998-11-26 |
WO1998052937A2 (fr) | 1998-11-26 |
JP2002502379A (ja) | 2002-01-22 |
AU7698198A (en) | 1998-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO995635L (no) | 3(5)-heteroaryl-substituerte pyrazoler som p38- kinaseinhibitorer | |
NO995695D0 (no) | Substituerte pyrazoler som p38-kinase-inhibitorer | |
DK1144403T3 (da) | Substituerede pyrazoler som p38-kinaseinhibitorer | |
ATE236167T1 (de) | P38 inhibitoren | |
EE200000610A (et) | p38 heterotsüklilised inhibiitorid | |
AU7726898A (en) | Pyrazole derivatives as p38 kinase inhibitors | |
ID21919A (id) | Heterosiklik yang mengandung nitrogen tersubstitusi sebagai inhibitor protein p38 kinase | |
ATE360618T1 (de) | Pyrazolderivate | |
AU3859999A (en) | 1,5-diaryl substituted pyrazoles as p38 kinase inhibitors | |
NO20000048L (no) | Triazolforbindelser og deres anvendelse som dopamin-D3- ligander | |
IS4621A (is) | C-4 ´ Umbreyttir adenosín kínasa latar | |
DK1027332T3 (da) | Hidtil ukendte lactametalloproteaseinhibitorer | |
DK0958287T3 (da) | Sulfamidmetalloprotease-inhibitorer | |
DK0891978T3 (da) | 5H-Thiazol(3,2-a)pyrimidinderivativer | |
IS5843A (is) | Fenýl janþín (yanthine) afleiður | |
ID21413A (id) | Turunan-turunan 1,3,8,-triaza-spiro (4,5) dekan-4-on | |
NO993628L (no) | Pyrazol-derivater | |
DE69800370D1 (de) | 4-(Alkoxyhydroxy)styryl-triazin Photoinitiatoren | |
AU2003200580A1 (en) | Substituted pyrazoles as P38 kinase inhibitors | |
ATE209649T1 (de) | Tetrahydroimidazo(2,1-a)isochinolinderivate | |
ID18481A (id) | 2-(3,5-difluorofenil)-3-(4-metilsulfonil)fenil)-2-siklopenten-1-on yang berguna sebagai inhibitor cox-2 | |
KR970703937A (ko) | 금속단백질 분해효소 억제제(Metallproteinase inhibitors) |